Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR…
Central Nervous System
-
-
Three pivotal MDD trial failures for Neumora lead to staffing cuts
Neumora Therapeutics is cutting its staff by 35% following Phase III trial failures of its multiple depressive disorder (MDD) candidate.…
-
Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
On 30 April 2026, Axsome Therapeutics announced the FDA approval of Auvelity (dextromethorphan + bupropion) for the treatment of agitation…
-
Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss
Corcept Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has shown two-year survival benefit above placebo, despite the trial having failed to…
-
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results…
-
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial…
-
AAN 2026: BlueRock reports positive safety data for bemdaneprocel in Parkinson’s
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, BlueRock Therapeutics, a wholly owned, independently operated subsidiary…
-
AAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competition
On April 20, at the 2026 American Academy of Neurology (AAN) meeting, Cabaletta Bio announced positive results from the Phase…
-
AAN 2026: new Vyvgart data show disease control in seronegative gMG
On 20 April, at the 2026 American Academy of Neurology (AAN) meeting, Argenx announced positive results from the Phase III,…
-
AAN 2026: frexalimab Phase II OLE data bolsters progressive MS ambitions
On 20 April, at the American Academy of Neurology (AAN) 2026 Annual Meeting, Sanofi presented three-year data from the open-label…
